Related Experiment Video

Updated: Oct 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Therapeutic approach to chronic hepatitis B and C in the dawn of the third millenium]

M Adler1, N Bourgeois

  • 1Service de Gastro-Entérologie et d'Hépato-Pancréatologie, Hôpital Erasme, U.L.B.

Revue Medicale De Bruxelles
|August 8, 2001
PubMed

Insights

This review covers the latest on hepatitis B and C virus infections, emphasizing vaccination and screening. Early detection and management are key to preventing severe liver disease and its complications.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Context:

  • Chronic liver disease is a significant global health concern.
  • Hepatitis B and C virus infections are leading causes of liver disease.
  • Advances in understanding viral pathogenesis and natural history are crucial.

Purpose:

  • To illustrate recent advancements in the epidemiology, pathogenesis, and natural history of hepatitis B and C virus infections.
  • To present practical management strategies for patients with chronic hepatitis B and C liver disease.
  • To advocate for universal hepatitis B vaccination and risk-based screening for hepatitis B and C.

Summary:

  • The review details current knowledge on hepatitis B and C virus infections, including their epidemiological trends, disease mechanisms, and disease progression.
  • It outlines effective patient management approaches for chronic liver conditions caused by these viruses.
  • Recommendations include promoting universal hepatitis B vaccination and screening at-risk populations for hepatitis B and C.

Impact:

  • Reducing morbidity and mortality associated with liver disease and its complications through vaccination and early intervention.
  • Empowering patients with knowledge of their evolving risks and available therapeutic options.
  • Improving public health outcomes by controlling the spread and impact of hepatitis B and C virus infections.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...